The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
about
When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyA Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel DiseasesA systematic review of barriers to and facilitators of the use of evidence by policymakersCost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitusHow long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.Oncology drug health technology assessment recommendations: Canadian versus UK experiences.Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in bulgaria.Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metforminSelecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the "Borda" Method: a Pilot StudyDo new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.The effectiveness of a preventive health program and vitamin D status in improving health-related quality of life of older Canadians.Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in BulgariaMulti-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair?Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial.Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis.Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.Benefit of adjunct universal rectal screening for Chlamydia genital infections in women attending Canadian sexually transmitted infection clinics.Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review.Economics of ramucirumab for metastatic colorectal cancer.Evidence for overuse of medical services around the world.GRADE EVIDENCE TO DECISION (EtD) FRAMEWORK FOR COVERAGE DECISIONS.Systematic overview of cost-effectiveness thresholds in ten countries across four continents.Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).Health Technology Assessment and Appraisal of Therapies for Rare Diseases.The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding DecisionsThe Economic Attractiveness of Targeted Radiotherapy: Value for Money?
P2860
Q24645229-39DCB7F7-8F7B-4192-8F1A-9AEEB5430282Q26775384-44B6D7A9-C241-42AF-A5C8-961AD5685E2CQ26827309-DE0E12BE-2453-4F0F-A655-AD15A560B945Q28600953-0DBCA0DF-6557-4A04-9B88-872B52E8C8C9Q30226892-4F77E944-45D6-4595-8DEA-3F2C6449D4A1Q33637512-A7988D11-B94F-4CC5-835A-052104A4A59CQ33933850-0523BAEB-2836-48A0-B556-239F5546A178Q34166892-36A4E170-B9E1-4F6F-9D10-335EAC6E9CCDQ34431985-19C37CA2-79A5-46CE-A729-80951205C385Q35522232-CE41773F-D732-4FFD-8867-5171B898ECA7Q35551069-1784F36B-8ECA-4946-83C3-3CB3F6F0B09DQ36358445-17049C1A-1277-4D47-9141-66F470C4335BQ36402852-D0D5118C-7C99-40A1-B8F4-2A5011CB0A90Q36594757-533FA6C2-A065-4455-919F-F5B4492D930DQ36618422-EE8FB6B9-0E48-42A8-BC03-EE6D611BC019Q37297978-48F2582A-182D-49EA-A830-0E8CB9CE1130Q37342575-2D550714-4E68-4DF5-A552-9B001C9D5E52Q37556655-AD7F30E4-9319-41E7-AF8A-1728F4CA72F3Q37604731-0ABE9A48-F4CE-43A0-801D-6CA62FE08795Q37701839-2990C84C-4B01-4C33-A867-33B03CCBD32EQ37782588-3C665C96-A1E4-4D4F-962D-70A5C5DE4248Q37834109-CB294886-A49B-43A1-894F-754EE4372343Q38586798-B67AF1A9-B663-45C4-8BBB-AC33B22FF9CFQ38608095-2DD07AD9-FA82-4CD6-B981-B077120DE5EEQ39003764-EF1C3B17-3056-411A-9F70-2E752DF14568Q39080255-FDFF2216-928D-4633-9628-99B660E70CBCQ40143602-266C0272-481E-4EB5-861B-65E6D731C199Q40405427-4026DDC3-A809-4133-82EA-ED21B3FA78EEQ41687828-B5B685A1-A5A8-46CA-810C-40E08485E447Q42406982-D64B6F07-A194-413D-A51E-B7CE441BD813Q47123934-3665EB6B-6475-4077-8C57-65524C78E5A4Q47583991-92FB1767-86F0-4E1F-9EF6-F415937F5C37Q48201652-92D72107-6323-498D-9B66-10ED5CF7A10BQ57412529-2A945054-01DD-4E88-BCD0-7E198CB9EDABQ58758454-3A34CE70-B568-49D1-A8C2-4EA257F95216
P2860
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of economic evidence ...... -making: to lambda and beyond.
@en
The role of economic evidence ...... -making: to lambda and beyond.
@nl
type
label
The role of economic evidence ...... -making: to lambda and beyond.
@en
The role of economic evidence ...... -making: to lambda and beyond.
@nl
prefLabel
The role of economic evidence ...... -making: to lambda and beyond.
@en
The role of economic evidence ...... -making: to lambda and beyond.
@nl
P2093
P1433
P1476
The role of economic evidence ...... -making: to lambda and beyond.
@en
P2093
Angela Rocchi
Devidas Menon
Elizabeth Miller
Shailendra Verma
P304
P356
10.1111/J.1524-4733.2007.00298.X
P577
2007-12-18T00:00:00Z